Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue trimmed its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 4.3% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 18,384 shares of the specialty pharmaceutical company’s stock after selling 824 shares during the quarter. State of Alaska Department of Revenue owned about 0.06% of Collegium Pharmaceutical worth $710,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Caxton Associates LP acquired a new stake in Collegium Pharmaceutical during the 1st quarter worth approximately $1,730,000. Foundry Partners LLC acquired a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at approximately $492,000. LSV Asset Management lifted its holdings in shares of Collegium Pharmaceutical by 188.7% in the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares during the period. O Shaughnessy Asset Management LLC lifted its holdings in shares of Collegium Pharmaceutical by 159.3% in the 1st quarter. O Shaughnessy Asset Management LLC now owns 45,735 shares of the specialty pharmaceutical company’s stock valued at $1,775,000 after buying an additional 28,100 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in shares of Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after buying an additional 17,942 shares during the period.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the transaction, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.30. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by company insiders.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $34.50 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. The business has a 50 day moving average price of $37.27 and a 200 day moving average price of $35.24. The company has a market capitalization of $1.11 billion, a P/E ratio of 13.37 and a beta of 0.95. Collegium Pharmaceutical, Inc. has a 1-year low of $21.40 and a 1-year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. Collegium Pharmaceutical’s revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.13 earnings per share. Sell-side analysts expect that Collegium Pharmaceutical, Inc. will post 5.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Piper Sandler reissued a “neutral” rating and issued a $37.00 price target on shares of Collegium Pharmaceutical in a report on Friday, October 11th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. HC Wainwright raised their price objective on Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Finally, Truist Financial raised their price objective on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.